Featured Story | By Nick Paul Taylor A big chunk of Pfizer’s plan to add $15 billion to sales just went up in smoke. Having gone over phase 2b data on cardiovascular drug vupanorsen, Pfizer has decided to return the rights to Ionis Pharmaceuticals, leaving it without a candidate it tipped to deliver peak sales of more than $3 billion. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Madrigal Pharmaceuticals has passed the first of two phase 3 nonalcoholic steatohepatitis (NASH) trials. With the study finding the ex-Roche drug reduces liver fat, Madrigal is heading to a more comprehensive efficacy readout with increased confidence in its chances of bucking the industry’s NASH losing streak. read more By Kyle LaHucik Taysha has gathered the data it needs to start a conversation with FDA and EU regulators about the approval pathway for its first gene therapy, which the biotech hopes will become the first approved treatment for a rare neurodegenerative disease that leads to death by a patient's early twenties. read more Sponsored by: TD2 Dive into the unique history of TD2 and learn how their approach to cancer drug development impacts clinical and partner success. read more By Sophia Sorensen For the third time in a week, Leaps by Bayer is contributing to another biotech's funding. This time it's for Gandeeva Therapeutics, a protein imaging company focused on identifying precision medicines. read more Sponsored by: Precision for Medicine Advances in cancer biomarker discovery, validation and clinical applications hinge on one critical resource: Quality biospecimens. Optimize and accelerate program success by sourcing and selecting the right samples. read more By Kyle LaHucik Flagship Pioneering-incubated Kaleido Biosciences confirmed it has shrunk its workforce. The company will run out of cash at some point in the second quarter, the biotech said in its latest earnings call in November 2021. The Flagship Pioneering-incubated biotech has lost most of its stock value since going public in 2019. read more By Gareth Macdonald Discovery scientists using traditional tech often need to make go-no-go decisions on sub-optimal data, says Charles River Laboratories, which has expanded its deal with SAMDI to try and give sponsors more information about candidate compounds. read more By Kevin Dunleavy With an FDA approval for Vabysmo to treat wet-age related macular degeneration (AMD) and diabetic macular edema (DME), Genentech and Roche have an antibody drug that could challenge Regeneron and Bayer's Eylea. The key edge for Vabysmo is that for most patients, it would allow fewer injections. read more By Fraiser Kansteiner Eli Lilly has designs on a new biologics factory in Ireland. It's investing some $445 million in the plant, with plans to hire 300 full-time staffers once the facility is complete. Details on the work planned for the site are slim, but Lilly made a point to say the facility will support its Alzheimer's portfolio, currently led by potential Aduhelm rival donanemab. read more By Andrea Park Adding Xbird’s machine learning AI-based analytics will help the Glooko platform better predict patients’ behavior and improve how they manage their diabetes by offering hyperpersonalized recommendations, the buyer said. read more By Dave Muoio Survey data from hundreds of 340B hospitals show hundreds of thousands of dollars lost among smaller critical access hospitals and millions among larger providers. read more By Ben Adams Biohaven is showing there’s no time for migraine when you’re in the fast lane as it doubles down on its literal marketing vehicles for the Nurtec NASCAR and IndyCar teams. read more Resources Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the CNS therapeutics market in 2022? This paper looks ahead in Alzheimer’s, Parkinson’s, DMD, psychiatric disorders, pain, and more. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Immuno-Oncology 360° Summit March 16-18, 2022 | New York Marriott Brooklyn Bridge Fierce Drug Safety Summit March 8-9, 2022 | Virtual Fierce BD&L Summit for Life Sciences March 15-16, 2022 | San Francisco, CA Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Forum May 16-17, 2022 | Virtual Event Fierce Health IT Summit May 24, 2022 | Virtual Event Fierce Digital Pharma: Engage June 14-15, 2022 | Huntington Beach, CA Fierce Pharma PR & Communications Summit West June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next-Gen Week June 29-30, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce MedTech Summit August 8-9, 2022 | Minneapolis, MN Fierce Diversity, Equity & Inclusion Forum August 15, 2022 | Virtual Event Fierce Biotech Summit October 10-11, 2022 | Location TBD Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce European Trial Master File Summit October 31- November 2, 2022 | London Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Boston, MA Fierce New Product Planning Summit November 30 - December 1, 2022 | Boston, MA | 
